透過您的圖書館登入
IP:3.145.125.13
  • 學位論文

製備活化的TMPRSS2胞外域以測試SARS-CoV-2進入細胞的抑制劑

Preparation of the activated TMPRSS2 ectodomain for assay of the inhibitors that block SARS-CoV-2 entry

指導教授 : 梁博煌

摘要


由嚴重急性呼吸道症候群冠狀病毒2型 (SARS-CoV-2) 引起的 2019 年冠狀病毒病 (COVID-19) 已在全球奪去許多人的生命,且仍在蔓延中。 病毒在與宿主細胞表面的血管緊張素轉化酶 2 (ACE2) 受體結合後,細胞表面的跨膜絲胺酸蛋白酶2 (TMPRSS2) 會切割 SARS-CoV-2 刺突蛋白,使病毒與細胞膜融合並進入細胞。 因此,已知藥物(如 camostat 和 nafamostat),藉著不可逆地抑制 TMPRSS2,從而抑制病毒進入。 如本文所述,我使用桿狀病毒感染的昆蟲細胞表達並激活TMPRSS2 胞外域以測定我們實驗室合成的抑制劑以及選定的天然產物和 FDA 批准的藥物。 這些化合物還使用弗林蛋白酶 (Furin) 和組織蛋白酶 L (Cathepsin L) 的試劑進行了分析,Furin 是一種人類細胞表面絲氨酸蛋白酶,可以與 TMPRSS2 分別在刺突蛋白的 S1/S2 及 S2' 位點切割。Cathepsin L一種參與切割刺突蛋白的細胞內蛋白酶,從而由胞內體釋放入侵的病毒。 根據 IC50 建立針對 TMPRSS2、Furin 和/或 Cathepsin L的抑制劑的構效關係,並通過分子嵌合計算 (docking) 對結構進行模擬以提供抑制的解釋。因此,這項研究提供了可能的 TMPRSS2、Furin 和/或 Cathepsin L 抑制劑來阻止 SARS-CoV-2 進入細胞。

並列摘要


Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in global fatalities and continues to spread. Transmembrane protease, serine 2 (TMPRSS2) on the surface of infected host cells cleaves SARS-CoV-2 spike protein, enabling the primed virus to fuse with the cell membrane and enter the cells after binding with the angiotensin-converting enzyme 2 (ACE2) receptor. Therefore, known antivirals like camostat and nafamostat irreversibly inhibit TMPRSS2 and virus entry. In this thesis, TMPRSS2 ectodomain was expressed using baculovirus-infected insect cells and activated to screen the inhibitors synthesized in our laboratory, as well as the selected natural products and FDA-approved drugs. These compounds were also assayed using the commercial kits to determine their inhibitory effects against Furin and Cathepsin L. Furin is a human cell-surface serine protease that works with TMPRSS2 to cleave the spike protein at the canonical S1/S2 and S2' site, respectively. Cathepsin L is an intracellular protease involved in cleaving the spike protein to release the invading virus from the endosome. Structure-activity relationships of the inhibitors against TMPRSS2, Furin, and/or Cathepsin L were established from the IC50 and the complex structures were modeled by the docking program to provide the structural rationale. Therefore, this study offers promising TMPRSS2, Furin, and/or Cathepsin L inhibitors to block SARS-CoV-2 entry.

參考文獻


Bestle D, Heindl MR, Limburg H, Van Lam van T, Pilgram O, Moulton H, Stein DA, Hardes K, Eickmann M, Dolnik O, Rohde C, Klenk HD, Garten W, Steinmetzer T, Böttcher-Friebertshäuser E. 2020. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance. 3, e202000786.
Butler, D. 2012. Clusters of coronavirus cases put scientists on alert. Nature 492, 166–167.
Chen CN, Lin CP, Huang KK, Chen WC, Hsieh HP, Liang PH, Hsu JT. 2005. Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3). Evid Based Complement Alternat Med 2, 209–215.
Chen YW, Lee MS, Lucht A, Chou FP, Huang W, Havighurst TC, Kim K, Wang JK, Antalis TM, Johnson MD, Lin CY. 2010. TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cells. Am. J. Pathol. 176, 2986–2996.
Cho SY, Kang JM, Ha YE, Park GE, Lee JY, Ko JH, Lee JY, Kim JM, Kang CI, Jo IJ, Ryu JG, Choi JR, Kim S, Huh HJ, Ki CS, Kang ES, Peck KR, Dhong HJ, Song JH, Chung DR, Kim YJ. 2016. MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: An epidemiological outbreak study. Lancet 388, 994–1001.

延伸閱讀